Molecular pathology of brain tumours - how will molecular and cell biology contribute to improved outcomes in patients with malignant brain tumours?

2.50
Hdl Handle:
http://hdl.handle.net/2436/30214
Title:
Molecular pathology of brain tumours - how will molecular and cell biology contribute to improved outcomes in patients with malignant brain tumours?
Authors:
Darling, John L.
Other Titles:
In: The 33rd Congress of the Czech Society of Pathologists, 2nd Satellite Symposium & Workshop on Molecular Pathology, Regional Centre Olomouc & Faculty of Medicine, Palacky University Olomouc, May 4–6, 2006, 20-22
Abstract:
Although in comparison to breast, lung and colon cancer, the brain is a relatively uncommon site for the development of cancer, the brain is the tenth most common site for the development of cancer in men and about the twelfth in women. This translates to about 6,000 individuals in the UK developing a primary malignant brain tumour every year. Cancer of the brain develops in two distinct age groups, although the types of tumour that develop in these two age groups differ markedly. There is a peak of incidence in the first decade of life, and brain tumours rank with leukaemia as a leading cause of cancer death in children. These tumours tend to be indolent low-grade astrocytomas or highly malignant primitive neuroectodermal tumours like medulloblastoma. However, the vast majority of brain tumours occur with increasing frequency in the sixth, seventh and eight decade of life and they are the second fastest growing cause of cancer death among those over 65. These tumours tend to be malignant astrocytomas particularly the most malignant variety, glioblastoma multiforme (GBM). Unlike lung cancer or malignant melanoma there is no strong evidence of an environmental carcinogen associated with the development of these tumours and no change in behaviour reduces risk.
Citation:
Biomedical Papers, 150(Suppl 1): 20-22
Publisher:
Czech Republic: Palacky University, Olomouc: Faculty of Medicine and Dentistry
Journal:
Biomedical Papers
Issue Date:
2006
URI:
http://hdl.handle.net/2436/30214
Additional Links:
http://publib.upol.cz/~obd/fulltext/Biomed/2006/Suppl.1/1.pdf
Type:
Meetings & Proceedings
Language:
en
Description:
The author is extremely grateful for the financial support by the Brain Research Trust, Samantha Dickson Research Trust, Brain Tumour UK, the Colin Oliphant Trust and the University of Wolverhampton. Abstract is provided here courtesy of Palacky University, Olomouc.
ISSN:
1213-8118
Appears in Collections:
Molecular Immunology Research Group ; Cancer Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorDarling, John L.-
dc.date.accessioned2008-06-19T13:37:16Z-
dc.date.available2008-06-19T13:37:16Z-
dc.date.issued2006-
dc.identifier.citationBiomedical Papers, 150(Suppl 1): 20-22en
dc.identifier.issn1213-8118-
dc.identifier.urihttp://hdl.handle.net/2436/30214-
dc.descriptionThe author is extremely grateful for the financial support by the Brain Research Trust, Samantha Dickson Research Trust, Brain Tumour UK, the Colin Oliphant Trust and the University of Wolverhampton. Abstract is provided here courtesy of Palacky University, Olomouc.en
dc.description.abstractAlthough in comparison to breast, lung and colon cancer, the brain is a relatively uncommon site for the development of cancer, the brain is the tenth most common site for the development of cancer in men and about the twelfth in women. This translates to about 6,000 individuals in the UK developing a primary malignant brain tumour every year. Cancer of the brain develops in two distinct age groups, although the types of tumour that develop in these two age groups differ markedly. There is a peak of incidence in the first decade of life, and brain tumours rank with leukaemia as a leading cause of cancer death in children. These tumours tend to be indolent low-grade astrocytomas or highly malignant primitive neuroectodermal tumours like medulloblastoma. However, the vast majority of brain tumours occur with increasing frequency in the sixth, seventh and eight decade of life and they are the second fastest growing cause of cancer death among those over 65. These tumours tend to be malignant astrocytomas particularly the most malignant variety, glioblastoma multiforme (GBM). Unlike lung cancer or malignant melanoma there is no strong evidence of an environmental carcinogen associated with the development of these tumours and no change in behaviour reduces risk.en
dc.language.isoenen
dc.publisherCzech Republic: Palacky University, Olomouc: Faculty of Medicine and Dentistryen
dc.relation.urlhttp://publib.upol.cz/~obd/fulltext/Biomed/2006/Suppl.1/1.pdfen
dc.subjectOncologyen
dc.subjectBrain Tumoursen
dc.subjectMalignant tumoursen
dc.subjectAstrocytomaen
dc.subjectGliomaen
dc.subjectGlioblastoma Multiformeen
dc.subjectGBMen
dc.subjectTP53en
dc.subjectChromosomal Aberrationsen
dc.subjectGenomicsen
dc.subjectDrug resistanceen
dc.subjectMolecular Biologyen
dc.titleMolecular pathology of brain tumours - how will molecular and cell biology contribute to improved outcomes in patients with malignant brain tumours?en
dc.title.alternativeIn: The 33rd Congress of the Czech Society of Pathologists, 2nd Satellite Symposium & Workshop on Molecular Pathology, Regional Centre Olomouc & Faculty of Medicine, Palacky University Olomouc, May 4–6, 2006, 20-22en
dc.typeMeetings & Proceedingsen
dc.identifier.journalBiomedical Papersen
All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.